Biocon Biologics gets $150 million from Goldman Sachs
Biocon Ltd in November announced that the board ...
Biocon Ltd in November announced that the board of its subsidiary Biocon Biologics has approved a Rs 1,125 crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “We are extremely pleased to welcome a capital injection by Goldman Sachs at this inflection point of Biocon Biologics’ journey in its quest for global leadership in providing affordable access through Biosimilar drugs. This transaction is a part of the overall strategic plan of value creation for our shareholders through Biocon Biologics.”
Related News.
-
November 2024 “Can’t be ignored”
-
November 2024 Record sales
-
November 2024 “INDIA HOLDS KEY”
-
November 2024 OYO on A buying spree
EDITOR'S DESK, Nov 2024
On November 6, the U.S. witnessed an extraordinary political turnaround as Donald J. Trump made a triumphant return, overcoming legal hurdles, a volatile political climate, and even assassination attempts. His victory in the 2024 presidential election is not only seen as a personal vindication but also as a momentous event for the global Indian diaspora, who have often viewed Trump as a reliable ally of India.
more...
Ads Spot
Comments.